150 related articles for article (PubMed ID: 22880112)
21. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).
Murakami H; Yamamoto N; Shibata T; Takeda K; Ichinose Y; Ohe Y; Yamamoto N; Takeda Y; Kudoh S; Atagi S; Satouchi M; Kiura K; Nogami N; Endo M; Watanabe H; Tamura T
Lung Cancer; 2014 Apr; 84(1):67-72. PubMed ID: 24530204
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
Tarhini A; Kotsakis A; Gooding W; Shuai Y; Petro D; Friedland D; Belani CP; Dacic S; Argiris A
Clin Cancer Res; 2010 Dec; 16(23):5900-7. PubMed ID: 21045083
[TBL] [Abstract][Full Text] [Related]
25. New advances in the second-line treatment of small cell lung cancer.
Hurwitz JL; McCoy F; Scullin P; Fennell DA
Oncologist; 2009 Oct; 14(10):986-94. PubMed ID: 19819917
[TBL] [Abstract][Full Text] [Related]
26. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
27. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
Yu G; Cai Q; Xu X; Shen Y; Xu K
PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.
Lee YG; Lee E; Kim I; Lee KW; Kim TM; Lee SH; Kim DW; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):670-5. PubMed ID: 25672586
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis.
Naito Y; Tamiya A; Tamiya M; Kimura Y; Hamaguchi M; Saijo N; Kanazu M; Tokura S; Shiroyama T; Morisita N; Omachi N; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
Medicine (Baltimore); 2017 Sep; 96(35):e7884. PubMed ID: 28858103
[TBL] [Abstract][Full Text] [Related]
30. Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
He J; Shao C; Hui SL; Zhang Z; Baker J; Dexter PR; Kachroo S; Jin F
Adv Ther; 2020 Jan; 37(1):552-565. PubMed ID: 31828610
[TBL] [Abstract][Full Text] [Related]
31. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
32. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
[TBL] [Abstract][Full Text] [Related]
33. Does activity of anticancer drugs in advanced cancer always translates in effectivity in early-stage high-risk disease?
Schrijvers DLAL
Ann Oncol; 2015 Sep; 26(9):2003-2005. PubMed ID: 26113647
[No Abstract] [Full Text] [Related]
34. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
37. Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC.
Kauffmann-Guerrero D; Kahnert K; Syunyaeva Z; Tufman A; Huber RM
Oncol Res Treat; 2018; 41(9):506-512. PubMed ID: 30086542
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
39. [Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
Li HM; Yuan P; Yu DK; Ma F; Tan WW; Feng T; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):504-9. PubMed ID: 27531263
[TBL] [Abstract][Full Text] [Related]
40. Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
Cao X; Ganti AK; Stinchcombe T; Wong ML; Ho JC; Shen C; Liu Y; Crawford J; Pang H; Wang X
Lung Cancer; 2020 Mar; 141():14-20. PubMed ID: 31926983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
